ANI Pharma investor presentation spotlights Rare Disease shift, targets 2026 net revenue of $1.1 billion
Reuters2026/08/07 11:09- ANI Pharmaceuticals reaffirmed 2026 guidance for total net revenue of $1.08 billion-$1.14 billion; adjusted non-GAAP EBITDA of $285 million-$300 million.
- Cortrophin Gel net revenue outlook reset to $520 million-$540 million from $540 million-$575 million; ILUVIEN guidance kept at $78 million-$83 million.
- Adjusted non-GAAP diluted EPS forecast maintained at $9.19-$9.69; adjusted non-GAAP gross margin expected at 59.9%-60.9%.
- Rare Disease expected to approach about 60% of 2026 revenue, with Cortrophin positioned as the main multi-year growth driver.
- Gout expansion became fully operational by end-June; Rare Disease sales force expanded about 50% to roughly 180 representatives.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Yelooo Integra Datanet corrects July securities holders registration report
Cakra Buana Resources Energi shareholder Republik Capital cuts stake to 9.3% from 11.3%
Preferred shares of South Korean companies are trading at a record 45% discount in ten years; Samsung's 110 trillion won buyback plan may help eliminate the "Korea discount"
Samsung Electronics' highly anticipated stock buyback plan is raising investor expectations that the South Korean giant will purchase non-voting preferred shares, narrowing their deep discount and setting a precedent for other companies.
Crypto prices
More
